Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
about
Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.Cancer nanomedicines: oversold or underappreciated?Barley grass extract causes apoptosis of cancer cells by increasing intracellular reactive oxygen species production.Nanoparticle-based drug delivery systems: What can they really do in vivo?New Modalities for Challenging Targets in Drug Discovery.Applying nanomedicine in maladaptive inflammation and angiogenesis.Targeted nanotechnologies for cancer intervention: a patent review (2010-2016).Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.An emerging integration between ionic liquids and nanotechnology: general uses and future prospects in drug delivery.Advances in the clinical translation of nanotechnology.Nanomaterial-Enabled Cancer Therapy.Nanomedicines: a theranostic approach for hepatocellular carcinoma.Biocatalytic virus capsid as nanovehicle for enzymatic activation of Tamoxifen in tumor cells.The Natural Fungal Metabolite Beauvericin Exerts Anticancer Activity In Vivo: A Pre-Clinical Pilot Study.Targeted nanoparticles for tumour radiotherapy enhancement-the long dawn of a golden era?Physalis Mottle Virus-Like Particles as Nanocarriers for Imaging Reagents and Drugs.Thermoresponsive pegylated bubble liposome nanovectors for efficient siRNA delivery via endosomal escape.Drug delivery to solid tumors: the predictive value of the multicellular tumor spheroid model for nanomedicine screening.Personalized Nanomedicine: A Revolution at the Nanoscale.A New Approach to Deliver Anti-cancer Nanodrugs with Reduced Off-target Toxicities and Improved Efficiency by Temporarily Blunting the Reticuloendothelial System with Intralipid.Enhanced anti-hepatocarcinoma efficacy by GLUT1 targeting and cellular microenvironment-responsive PAMAM-camptothecin conjugate.Dendrimers in combination with natural products and analogues as anti-cancer agents.Efficient Uptake of 177 Lu-Porphyrin-PEG Nanocomplexes by Tumor Mitochondria for Multimodal-Imaging-Guided Combination Therapy.Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate.Tailored Approaches in Drug Development and Diagnostics: From Molecular Design to Biological Model Systems.Formulation of Poloxamers for Drug Delivery.Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8.Theranostic Hyaluronic Acid-Iron Micellar Nanoparticles for Magnetic-Field-Enhanced in vivo Cancer Chemotherapy.Therapeutic prospects of microRNAs in cancer treatment through nanotechnology.Capturing "Extraordinary" Soft-Assembled Charge-Like Polypeptides as a Strategy for Nanocarrier Design.The role of hydrophobic modification on hyaluronic acid dynamics and self-assembly.Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy - An illustration with firsthand examples.Drug Delivery Nanosystems for the Localized Treatment of Glioblastoma Multiforme.Application of Light Scattering Techniques to Nanoparticle Characterization and Development.Advantages and Limitations of Current Techniques for Analyzing the Biodistribution of NanoparticlesMulti-modal characterization of vasculature and nanoparticle accumulation in five tumor xenograft modelsImaging Nanomedicine-Based Drug Delivery: a Review of Clinical StudiesGeneral synthesis of silica-based yolk/shell hybrid nanomaterials and tumor vasculature targetingFrom 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancerRecent advances in "smart" delivery systems for extended drug release in cancer therapy
P2860
Q30354652-3E820401-C93A-4D1E-BC4B-ACE6895CE7B4Q33602272-B14B0F3E-2F76-4645-8B20-F43E311ECC33Q33742160-6D9CB584-1570-48CA-8111-046D90605625Q33772186-80F5C0FB-81C2-4126-9C00-7428DB410DFFQ38289100-6DEC8F31-80C3-4869-B1BC-E4312DA0B98CQ38557650-1AF60F7A-2E38-4E19-BBC4-5A27AEF81FC2Q38670236-877EC9A1-474E-4A6C-8432-99215E7F9034Q38676164-C9DBB645-7988-4FF6-B9F8-FA6205695EC1Q38681052-BDE05D96-FB41-47A6-9133-7E64CBC5A41CQ39130471-7305FA2E-A366-4328-97DF-FCE865E95D7DQ39323096-418FCF34-F34B-44DB-96D4-F40DBBF9C132Q40051560-1C30F54E-7B45-4F6F-A002-389E3A98DC38Q40260796-DA4B6516-6CA9-4801-89A1-FAC5A6117DB9Q41669372-9FF3702E-8756-4D09-99AB-0B9A4ED857A0Q42330851-88087EDA-EB94-4D77-AB01-78DB97F195EEQ44877126-02D26F9F-5CD9-4847-885A-82E897E1ACCBQ45867909-72AB92AD-B414-4469-AB40-48ACA2D5F29CQ46914962-9A14FC59-AAE9-48B6-B251-155ACC2C8B12Q47159637-D0D1B0D7-18A3-4EB8-B843-A53553A7EA23Q47162722-B5A6240E-C005-4A74-9A87-77456AA7DA95Q47276992-AE77D8E6-39FA-4059-9304-E5728291B68BQ47333126-E23BB0BB-5EAD-4578-8FF8-41EF48DCB320Q47391185-2270C5BD-9C88-47D1-96B4-70C7CD721AC8Q47571555-3D444C22-9FE9-4141-8C03-B4661697E812Q47690085-D5E69D13-31AE-44CC-8A84-7129309801B3Q47711535-65A5A810-FC80-4B8C-8B18-6115058953EDQ47832898-8911E45F-62B4-4764-A8BD-7DFA53578BA8Q48097863-630AA72A-F484-441C-829C-A0EEF6018762Q48219725-58AB5663-9E5C-4CE8-8881-E9C1311BE4ABQ48684399-3CCFCBC1-BA97-4814-BDC6-02DC9AE32DC8Q49569989-F8F94D93-3E87-403E-8AC7-38469D178BEEQ52561274-146BE6A2-60DB-42E4-8895-83FC98B7A250Q54970083-F4D40328-2E13-4F43-B5B5-5CF03B0EB879Q55516366-CE67DB5F-3D04-4E84-A4D4-B23957676A9DQ57181636-66A897FC-E352-4CAA-AF38-E6327AED479FQ57181925-5AFD0C9B-A3DD-4D4F-BF1B-23007B650B59Q58147367-678EB294-107C-4E8B-AA68-A1BD0246C124Q58560988-469AB72D-94EB-485D-BCE8-AFF35AD2375AQ58694509-EF66BCFA-202C-4A5A-8D4B-EF8A1F86C9D0Q58735813-2A19B643-0AAD-4838-81B3-7D84473BBB22
P2860
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Challenges and strategies in a ...... pment: An industry perspective
@ast
Challenges and strategies in a ...... pment: An industry perspective
@en
Challenges and strategies in a ...... pment: An industry perspective
@nl
type
label
Challenges and strategies in a ...... pment: An industry perspective
@ast
Challenges and strategies in a ...... pment: An industry perspective
@en
Challenges and strategies in a ...... pment: An industry perspective
@nl
prefLabel
Challenges and strategies in a ...... pment: An industry perspective
@ast
Challenges and strategies in a ...... pment: An industry perspective
@en
Challenges and strategies in a ...... pment: An industry perspective
@nl
P2093
P1476
Challenges and strategies in a ...... pment: An industry perspective
@en
P2093
Gert Storm
Jennifer I Hare
Marianne B Ashford
Sanyogitta Puri
Simon T Barry
P356
10.1016/J.ADDR.2016.04.025
P407
P50
P577
2016-04-29T00:00:00Z